American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).

The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.

Once-week carfilzomib may represent a more convenient treatment option for patients with relapsed/refractory multiple myeloma (R/R MM), according to data from the phase III ARROW trial.

The EGFR tyrosine kinase inhibitor (TKI) dacomitinib showed superior overall survival (OS) vs gefitinib in patients with treatment-naïve EGFR-positive non-small-cell lung cancer (NSCLC) in the final analysis of the ARCHER 1050 study.

Adjuvant treatment with a modified FOLFIRINOX (mFOLFIRINOX) regimen extends overall survival (OS) by nearly 20 months compared with standard chemotherapy in patients with nonmetastatic pancreatic ductal adenocarcinoma (PDAC), results of a phase III trial have shown.

Clinical use of a 21-gene expression assay can help spare adjuvant chemotherapy in many patients with early breast cancer, according to results of a large trial hailed by experts as practice-changing.